Australian reporter Iain Finlay has died by euthanasia after a lengthy battle with a rare disease called amyloidosis. He was 89. Finlay, a former journalist for the Australian Broadcasting ...

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...

Treatment modalities include liver transplantation for transthyretin-related (ATTR) amyloidosis, elimination of inflammation in amyloid A (AA) amyloidosis and intensive chemotherapy in ...

He was suffering from from amyloidosis, a disorder in which amyloid protein builds up in the organs. Veteran journalist Iain Finlay, 89, died by euthanasia at home. He battled amyloidosis ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Good day, and welcome to Arcutis Biotherapeutics 2025 first-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would ...

Good day and welcome to Arcutis Biotherapeutics' 2025 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation ...

Arcutis Biotherapeutics Inc. reported its Q1 2025 results, showcasing a slight earnings beat with an EPS of -$0.20 against a forecast of -$0.21. The company also surpassed revenue expectations ...

Investing.com -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported first quarter 2025 financial results that exceeded analyst expectations for revenue, but the stock fell 6.9% following the ...

ZORYVE foam 0.3% shows significant efficacy for scalp and body psoriasis, with FDA review anticipated by May 2025. Arcutis Biotherapeutics, Inc. announced positive results from a pivotal Phase 3 ...

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. (O.F.C., S.D ...